Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SYEDA vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Syeda is a combination of drospirenone and ethinyl estradiol, a contraceptive that suppresses gonadotropins, primarily inhibiting ovulation; drospirenone has antimineralocorticoid and antiandrogenic activity.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Prevention of pregnancy
Prevention of pregnancy (FDA-approved)
1 tablet (3 mg drospirenone / 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo tablets.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
Terminal elimination half-life of 12-15 hours; allows twice-daily dosing for sustained therapeutic levels.
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Ethinyl estradiol is metabolized primarily by CYP3A4; drospirenone is metabolized by CYP3A4 and to a lesser extent by CYP1A1 and CYP2C19.
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Urinary excretion (40-60% as unchanged drug and metabolites); biliary/fecal elimination accounts for 15-25%.
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
98% bound to albumin and alpha-1-acid glycoprotein.
~99% bound to serum albumin and sex hormone-binding globulin.
0.8-1.2 L/kg; indicates extensive tissue distribution.
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Oral: 60-70% due to first-pass metabolism.
Oral: ~70% due to first-pass metabolism.
Contraindicated in patients with severe renal impairment (Cr Cl <30 m L/min). For mild to moderate impairment (Cr Cl 30-50 m L/min), use with caution; monitor potassium levels due to drospirenone's antimineralocorticoid effect.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Contraindicated in patients with hepatic impairment (Child-Pugh class B or C). For mild hepatic impairment (Child-Pugh class A), use with caution; monitor liver function.
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
Not indicated for use in pediatric patients before menarche. For postmenarchal adolescents, dosing is same as adult: 1 tablet orally once daily for 21 days, then 7 days placebo.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
Not indicated for use in postmenopausal women. No geriatric-specific dosing guidelines; use is inappropriate in this population.
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age and heavy smoking (≥15 cigarettes/day), particularly in women over 35. Women over 35 who smoke should not use combination oral contraceptives.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Thromboembolic disorders and other vascular events, cardiovascular disease, liver disease, hypertension, gallbladder disease, carbohydrate and lipid metabolism effects, headache, bleeding irregularities, depression, and use in women with hereditary angioedema.
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Renal impairment, adrenal insufficiency, hepatic disease, high risk of thromboembolic disorders, cerebrovascular or coronary artery disease, uncontrolled hypertension, diabetes with vascular involvement, headaches with focal neurological symptoms, major surgery with prolonged immobilization, known or suspected pregnancy, undiagnosed abnormal uterine bleeding, current or past breast cancer or other estrogen-sensitive neoplasia, liver tumors, and hypersensitivity to any component.
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
No known food interactions. Grapefruit juice may reduce metabolism of ethinyl estradiol, but effect is not clinically significant. Avoid concurrent use with St. John's Wort, which induces CYP3A4 and reduces contraceptive efficacy.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
FDA Pregnancy Category X. First trimester: high risk of neural tube defects, cardiac anomalies, and cleft palate. Second and third trimesters: risk of fetal adrenal suppression, virilization of female fetuses if androgenic progestins are present. Contraindicated in pregnancy due to teratogenicity and fetal harm.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
Present in breast milk; M/P ratio not reported. Not recommended during breastfeeding due to potential adverse effects on infant development and hormonal disruption. Use alternative contraception if breastfeeding.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
Contraindicated in pregnancy; no dose adjustments recommended. Discontinue immediately if pregnancy occurs.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
SYEDA (drospirenone/ethinyl estradiol) is a combined oral contraceptive. Use in women with renal impairment is contraindicated due to drospirenone's antimineralocorticoid effect. Monitor potassium levels in patients on NSAIDs, ACE inhibitors, or potassium-sparing diuretics. Increased risk of venous thromboembolism (VTE) compared to levonorgestrel-containing pills. Avoid in patients with migraine with aura, history of VTE, or breast cancer. Do not use in patients with liver tumors or acute hepatitis.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Take one tablet daily at the same time, regardless of meals. Missing a dose increases pregnancy risk.,Use backup contraception (e.g., condoms) for 7 days if you miss one or more active pills.,Common side effects include nausea, breast tenderness, and spotting; these usually improve after 1–3 cycles.,Do not smoke while taking this medication, especially if over 35, due to increased risk of blood clots.,Immediately report symptoms of VTE: sudden leg swelling/pain, chest pain, shortness of breath, or vision changes.,This medication does not protect against HIV or other sexually transmitted infections.
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SYEDA vs AFIRMELLE, answered by our medical review team.
SYEDA is a Oral Contraceptive that works by Syeda is a combination of drospirenone and ethinyl estradiol, a contraceptive that suppresses gonadotropins, primarily inhibiting ovulation; drospirenone has antimineralocorticoid and antiandrogenic activity.. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SYEDA and AFIRMELLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SYEDA is: 1 tablet (3 mg drospirenone / 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo tablets.. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SYEDA and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SYEDA is classified as Category C. FDA Pregnancy Category X. First trimester: high risk of neural tube defects, cardiac anomalies, and cleft palate. Second and third trimesters: risk of fetal adrenal suppression, vi. AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.